A retrospective study of cardiovascular events related to the use of Glucose lowering drug treatment in Primary Care - ROSE

Study identifier:NIS-CSE-DUM-2010/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Retrospective Epidemiological Study to Investigate Outcome and Mortality with Glucose Lowering Drug Treatment in Primary Care

Medical condition

Diabetes Type II

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

58326

Study type

Observational

Age

N/A

Date

Study Start Date: 01 May 2010

Primary Completion Date: 01 Aug 2011

Study Completion Date: 01 Aug 2011

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Uppsala, Sweden

Arms	Assigned Interventions
1 Diabetes type II patients, according to medical records, prescriptions or lab results, followed for >6 months after diagnosis.	-

"There is no result for the study"

Documents available

CSR-NIS-CSE-DUM-2010-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Sweden Study Information

+46 (0)8 553 26 000

Investigators

Principal Investigator

Leif Lohm

AstraZeneca Nordic, Södertälje